Trials / Completed
CompletedNCT00038506
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abacavir/lamivudine/zidovudine | |
| DRUG | tenofovir |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2004-08-01
- Completion
- 2004-08-01
- First posted
- 2002-06-03
- Last updated
- 2015-04-08
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00038506. Inclusion in this directory is not an endorsement.